Clostridium butyricum protects the epithelial barrier by maintaining tight junction protein expression and regulating microflora in a murine model of dextran sodium sulfate-induced colitis

References

• Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults: American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 2010;105:501–523.
   PubMed Web of Science ®Google Scholar
• Deitch EA. Bacterial translocation or lymphatic drainage of toxic products from the gut: what is important in human beings? Surgery. 2002;131:241–244.
   PubMed Web of Science ®Google Scholar
• Heller F, Florian P, Bojarski C, et al. Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution. Gastroenterology. 2005;129:550–564.
   PubMed Web of Science ®Google Scholar
• Schmitz H, Barmeyer C, Fromm M, et al. Altered tight junction structure contributes to the impaired epithelial barrier function in ulcerative colitis. Gastroenterology. 1999;116:301–309.
   PubMed Web of Science ®Google Scholar
• Johnson-Henry KC, Donato KA, Shen-Tu G, et al. Lactobacillus rhamnosus strain GG prevents enterohemorrhagic Escherichia coli O157: H7-induced changes in epithelial barrier function. Infect Immun. 2008;76:1340–1348.
   PubMed Web of Science ®Google Scholar
• Resta-Lenert S, Barrett KE. Probiotics and commensals reverse TNF-a and IFN-r induced dysfunction in human intestinal epithelial cells. Gastroenterology. 2006;130:731–746.
   PubMed Web of Science ®Google Scholar
• Qin H, Zhang Z, Hang X, et al. L. plantarum prevents enteroinvasive Escherichia coli-induced tight junction proteins changes in intestinal epithelial cells. BMC Microbiol. 2009;9:63–71.
   PubMed Web of Science ®Google Scholar
• Dnucan SH, Hold GL, Barcenilla A, et al. Roseburia intestina-lis sp. nov., a novel saccharolytic, butyrate-producing bacterium from human faeces. Int J Syst Evol Microbiol. 2002;52:1615–1620.
   PubMed Web of Science ®Google Scholar
• Zhang HQ, Li AL, Qiao G, et al. Therapeutic effects of A Tai Ning on oxazolone induced ulcerative colitis in rats. Shijie Huaren Xiaohua Zazhi. 2008;16:3036–3042.
   Google Scholar
• Zhang HQ, Ding TT, Zhao JS, et al. Therapeutic effects of Clostridium butyricum on experimental colitis induced by oxazolone in rats. World J Gastroenterol. 2009;15:1821–1828.
   PubMed Web of Science ®Google Scholar
• Hudcovic T, Kolinska J, Klepetar J, et al. Protective effect of Clostridium tyrobutyricum in acute dextran sodium sulphate-induced colitis: differential regulation of tumour necrosis factor-α and interleukin-18 in BALB/c and severe combined immunodeficiency mice. Clin Exp Immunol. 2012;167:356–365.
   PubMed Web of Science ®Google Scholar
• Hamamoto N, Maemura K, Hirata I, et al. Inhibition of dextran sulphate sodium (DSS)-induced colitis in mice by intracolonically administered antibodies against adhesion molecules (endothelial leucocyte adhesion molecule-1 (ELAM-1) or intercellular adhesion molecule-1 (ICAM-1)). Clin Exp Immunol. 1999;117:462–468.
   PubMed Web of Science ®Google Scholar
• Dieleman LA, Palmen MJ, Akol H, et al. Chronic experimental colitis induced by dextran sulphate sodium (DSS) is characterized by Th1 and Th2 cytokines. Clin Exp Immunol. 1998;114:385–391.
   PubMed Web of Science ®Google Scholar
• Ohkusa T. Production of experimental ulcerative colitis in hamsters by dextran sulfate sodium and changes in intestinal microflora. Nihon Shokakibyo Gakkai Zasshi. 1985;82:1327–1336.
   PubMedGoogle Scholar
• Hall LJ, Faivre E, Quinlan A, et al. Induction and activation of adaptive immune populations during acute and chronic phases of a murine model of experimental colitis. Dig Dis Sci. 2011;56:79–89.
   PubMed Web of Science ®Google Scholar
• Melgar S, Karlsson A, Michaëlsson E. Acute colitis induced by dextran sulfate sodium progresses to chronicity in C57BL/6 but not in BALB/c mice: correlation between symptoms and inflammation. Am J Physiol Gastrointest Liver Physiol. 2005;288:G1328–G1338.
   PubMed Web of Science ®Google Scholar
• Honda K, Littman DR. The microbiome in infectious disease and inflammation. Annu Rev Immunol. 2012;30:759–795.
   PubMed Web of Science ®Google Scholar
• Sepehri S, Kotlowski R, Bernstein CN, et al. Microbial diversity of inflamed and noninflamed gut biopsy tissues in inflammatory bowel disease. Inflamm Bowel Dis. 2007;13:675–683.
   PubMed Web of Science ®Google Scholar
• Elson CO, Cong Y, McCracken VJ, et al. Experimental models of inflammatory bowel disease reveal innate, adaptive, and regulatory mechanisms of host dialogue with the microbiota. Immunol Rev. 2005;206:260–276.
   PubMed Web of Science ®Google Scholar
• Sellon RK, Tonkonogy S, Schultz M, et al. Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interleukin-10-deficient mice. Infect Immun. 1998;66:5224–5231.
   PubMed Web of Science ®Google Scholar
• Dieleman LA, Hoentjen F, Qian BF, et al. Reduced ratio of protective versus proinflammatory cytokine responses to commensal bacteria in HLA-B27 transgenic rats. Clin Exp Immunol. 2004;136:30–39.
   PubMed Web of Science ®Google Scholar
• Hudcovic T, Stepankova R, Cebra J, et al. The role of microflora in the development of intestinal inflammation: acute and chronic colitis induced by dextran sulfate in germ-free and conventionally reared immunocompetent and immunodeficient mice. Folia Microbiol (Praha). 2001;46:565–572.
   PubMed Web of Science ®Google Scholar
• Kong Q, He GQ, Jia JL, et al. Oral administration of Clostridium butyricum for modulating gastrointestinal microflora in mice. Curr Microbiol. 2011;62:512–517.
   PubMed Web of Science ®Google Scholar
• Araki Y, Andoh A, Takizawa J, et al. Oral administration of a product derived from Clostridium butyricum in rats. Int J Mol Med. 2004;13:577–580.
   PubMed Web of Science ®Google Scholar
• Takahashi M, Taguchi H, Yamaguchi H, et al. The effect of probiotic treatment with Clostridium butyricum on enterohemorrhagic Escherichia coli O157: H7 infection in mice. FEMS Immunol Med Microbiol. 2004;41:219–226.
   PubMedGoogle Scholar
• Round JL, Mazmanian SK. The gut microbiota shapes intestinal immune responses during health and disease. Nat Rev Immunol. 2009;9:313–323.
   PubMed Web of Science ®Google Scholar
• Poritz LS, Garver KI, Green C, et al. Loss of the tight junction protein ZO-1 in dextran sulfate sodium induced colitis. J Surg Res. 2007;140:12–19.
   PubMed Web of Science ®Google Scholar
• Mennigen R, Nolte K, Rigcken E, et al. Probiotic mixture VSL#3 protects the epithelial barrier by maintaining tight junction protein expression and preventing apoptosis in a murine model of colitis. Am J Physiol Gastrointest Liver Physiol. 2009;296:G1140–G1149.
   PubMed Web of Science ®Google Scholar
• Podolsky DK. Inflammatory bowel disease. N Engl J Med. 2002;347:417–429.
   PubMed Web of Science ®Google Scholar
• Ye D, Ma TY. Cellular and molecular mechanisms that mediate basal and tumour necrosis factor-α-induced regulation of myosin light chain kinase gene activity. J Cell Mol Med. 2008;12:1331–1346.
   PubMed Web of Science ®Google Scholar
• Al-Sadi R, Ye D, Said HM, et al. Cellular and molecular mechanism of interleukin-1β modulation of Caco-2 intestinal epithelial tight junction barrier. J Cell Mol Med. 2011;15:970–982.
   PubMed Web of Science ®Google Scholar
• Schmitz H, Fromm M, Bentzel CJ, et al. Tumor necrosis factor-alpha (TNFα) regulates the epithelial barrier in the human intestinal cell line HT-29/B6. J Cell Sci. 1999;112:137–146.
   PubMed Web of Science ®Google Scholar
• Marchiando AM, Shen L, Graham WV, et al. The epithelial barrier is maintained by in vivo tight junction expansion during pathologic intestinal epithelial shedding. Gastroenterology. 2011;140:1208–1218.
   PubMed Web of Science ®Google Scholar
• John LJ, Fromm M, Schulzke JD. Epithelial barriers in intestinal inflammation. Antioxid Redox Signal. 2011;15:1255–1270.
   PubMed Web of Science ®Google Scholar
• Amasheh M, Grotjohann I, Amasheh S, et al. Regulation of mucosal structure and barrier function in rat colon exposed to tumor necrosis factor alpha and interferon gamma in vitro: a novel model for studying the pathomechanisms of inflammatory bowel disease cytokines. Scand J Gastroenterol. 2009;44:1226–1235.
   PubMed Web of Science ®Google Scholar
• Tessner TG, Cohn SM, Schloemann S, et al. Prostaglandins prevent decreased epithelial cell proliferation associated with dextran sodium sulfate injury in mice. Gastroenterology. 1998;115:874–882.
   PubMed Web of Science ®Google Scholar
• Sakuraba H, Ishiguro Y, Yamagata K, et al. Transforming growth factor-{beta} regulates susceptibility of epithelial apoptosis in murine model of colitis. Ann N Y Acad Sci. 2004;1029:382–384.
   PubMed Web of Science ®Google Scholar
• Murano M, Maemura K, Hirata I, et al. Therapeutic effect of intracolonically administered nuclear factor kappa B (p65) antisense oligonucleotide on mouse dextran sulphate sodium (DSS)-induced colitis. Clin Exp Immunol. 2000;120:51–58.
   PubMed Web of Science ®Google Scholar
• Dijkstra G, Moshage H, Jansen PL. Blockade of NF-kappaB activation and donation of nitric oxide: new treatment options in inflammatory bowel disease? Scand J Gastroenterol. 2002;236:37–41.
   Web of Science ®Google Scholar
• Nishikawa J, Kudo T, Sakata S, et al. Diversity of mucosa-associated microbiota in active and inactive ulcerative colitis. Scand J Gastroenterol. 2009;44:180–186.
   PubMed Web of Science ®Google Scholar
• Lakatos PL, Fischer S, Lakatos L, et al. Current concept on the pathogenesis of inflammatory bowel disease-crosstalk between genetic and microbial factors: pathogenic bacteria and altered bacterial sensing or changes in mucosal integrity take “toll”? World J Gastroenterol. 2006;12:1829–1841.
   PubMed Web of Science ®Google Scholar